本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Apellis Pharmaceuticals Inc.

20.19
-0.1400-0.69%
成交量:45.48万
成交额:922.90万
市值:25.55亿
市盈率:56.37
高:20.58
开:20.06
低:20.06
收:20.33
52周最高:35.72
52周最低:16.10
股本:1.27亿
流通股本:7,811.99万
量比:0.56
换手率:0.58%
股息:- -
股息率:- -
每股收益(TTM):0.3581
每股收益(LYR):-1.5970
净资产收益率:14.10%
总资产收益率:5.13%
市净率:6.37
市盈率(LYR):-12.64

数据加载中...

2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/13

重要事件披露

Form 8-K - Current report
2025/01/06

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/12/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/12/11

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/22

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/22

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/08

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/09/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/08

重要事件披露

Form 8-K - Current report
2024/08/01

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]